Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Valion Bio (TIVC) EBT Margin (2021 - 2025)

Valion Bio has reported EBT Margin over the past 5 years, most recently at 1697.95% for Q3 2025.

  • For Q3 2025, EBT Margin fell 56223.0% year-over-year to 1697.95%; the TTM value through Sep 2025 reached 1533.61%, down 85628.0%, while the annual FY2024 figure was 730.77%, 143179.0% up from the prior year.
  • EBT Margin for Q3 2025 was 1697.95% at Valion Bio, up from 2248.84% in the prior quarter.
  • Over five years, EBT Margin peaked at 419.81% in Q1 2021 and troughed at 2248.84% in Q2 2025.
  • A 5-year average of 878.82% and a median of 589.2% in 2021 define the central range for EBT Margin.
  • Biggest five-year swings in EBT Margin: surged 37273bps in 2024 and later plummeted -170802bps in 2025.
  • Year by year, EBT Margin stood at 589.2% in 2021, then rose by 6bps to 552.94% in 2022, then dropped by -14bps to 628.57% in 2023, then crashed by -30bps to 818.33% in 2024, then plummeted by -107bps to 1697.95% in 2025.
  • Business Quant data shows EBT Margin for TIVC at 1697.95% in Q3 2025, 2248.84% in Q2 2025, and 2151.43% in Q1 2025.